Director’s Major Stock Sale Shakes Up PTC Therapeutics!

New insider activity at PTC Therapeutics ( (PTCT) ) has taken place on September 11, 2025.

Director David Southwell recently sold 12,000 shares of PTC Therapeutics stock, amounting to a total transaction value of $700,080.

Recent Updates on PTCT stock

In the last 24 hours, PTC Therapeutics has been the focus of several analyst updates following the FDA’s issuance of a complete response letter (CRL) regarding their drug vatiquinone for Friedreich’s ataxia. Morgan Stanley lowered its price target due to the CRL, which necessitates further trials before resubmission, impacting the firm’s model for vatiquinone. Similarly, BofA reduced its price target, citing the delay in the drug’s potential market launch to 2028 and a decreased likelihood of success. Despite these setbacks, JPMorgan added PTC Therapeutics to its Analyst Focus List, viewing the selloff as a buying opportunity, suggesting the CRL’s impact is already reflected in the stock price. The completion of a clinical study on vatiquinone in young children with Friedreich ataxia was also noted, potentially offering new treatment avenues and influencing future stock performance.

Spark’s Take on PTCT Stock

According to Spark, TipRanks’ AI Analyst, PTCT is a Neutral.

PTC Therapeutics’ overall score is primarily influenced by its financial instability and high leverage, which pose significant risks. However, the company shows potential for recovery with strong gross profit margins and recent strategic advancements, particularly the launch of Sephience. The stock’s undervaluation and positive earnings call sentiment further support its growth prospects, despite regulatory challenges.

To see Spark’s full report on PTCT stock, click here.

More about PTC Therapeutics

YTD Price Performance: 27.14%

Average Trading Volume: 1,223,955

Technical Sentiment Signal: Buy

Current Market Cap: $4.63B